Jun 09, 2022 / 03:00PM GMT
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
Hi, everyone. My name is Maurice Raycroft and I'm one of the biotech analysts at Jefferies. I would like to introduce Yvonne Greenstreet, the CEO of Alnylam. Great to see you, Yvonne, and thanks so much for joining us today.
Yvonne L. Greenstreet - Alnylam Pharmaceuticals, Inc. - CEO & Director
Thanks, Maurice. And a pleasure to be here and to be in person again across the live audience. It's a lot more fun doing it with you today. So I'm just going to make a few introductory remarks if that's the case but I just want to remind people that Alnylam is the leading RNAi company. We're incredibly proud of our progress. We now have 4 marketed medicines, 3 that we are commercializing ourselves ONPATTRO, GIVLAARI and OXLUMO and Leqvio which has been commercialized by Novartis. We have a very rich clinical pipeline, which continues to deliver exciting progress. And you may have seen today that we are sharing the results from a Phase II study with Cemdisiran in patients with IgA nephropathy.
Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers